Table 3.
Multivariate analysis with covariate considerations
| HR (95% CI) | P | P (unadjusted) | |
|---|---|---|---|
| Relapse incidence | |||
| UCB vs MUD | 0.59 (0.31-1.1) | .84 | .12 |
| MSD vs MUD | 0.71 (0.34-1.5) | 1 | |
| MSD vs UCB | 1.2 (0.59-2.5) | 1 | .59 |
| MSD vs dUCB | 0.91 (0.4-2) | 1 | .8 |
| Chemo-based vs TBI-based | 0.77 (0.45-1.3) | .36 | |
| Age at HCT (spline 1) | 0.86 (0.76-0.97) | .015 | |
| Age at HCT (spline 2) | 1.2 (1-1.4) | .03 | |
| LFS | |||
| UCB vs MUD | 1 (0.62-1.7) | 1 | .9 |
| MSD vs MUD | 0.83 (0.45-1.4) | 1 | .48 |
| MSD vs UCB | 0.77 (0.45-1.3) | 1 | .37 |
| MSD vs dUCB | 0.56 (0.3-1) | .406 | .058 |
| Age at HCT (spline 1) | 0.88 (0.8-0.96) | .0054 | |
| Age at HCT (spline 2) | 1.1 (1-1.3) | .012 | |
| BuCy-like vs BuFlu | 0.43 (0.17-1.1) | 077 | |
| BuCy-like vs BuMel-like | 0.91 (0.5-1.7) | .77 | |
| BuCy-like vs Other | 0.77 (0.4-1.4) | .39 | |
| BuCy-like vs TBI-based | 1 (0.56-1.8) | .99 | |
| Nonrelapse mortality | |||
| UCB vs MUD | 1.6 (0.67-3.8) | 1 | .28 |
| MSD vs MUD | 1.1 (0.37-3.1) | 1 | .89 |
| MSD vs UCB | 0.67 (0.28-1.6) | 1 | .37 |
| MSD vs dUCB | 0.42 (0.16-1.1) | .497 | .071 |
| Chemo-based vs TBI-based | 1.2 (0.62-2.2) | .59 | |
| Age at HCT (spline 1) | 0.94 (0.81-1.1) | .37 | |
| Age at HCT (spline 2) | 1.1 (0.9-1.3) | .49 | |
| OS | |||
| UCB vs MUD | 1 (0.59-1.8) | 1 | .92 |
| MSD vs MUD | 0.67 (0.36-1.3) | 1 | .22 |
| MSD vs UCB | 0.67 (0.36-1.2) | 1 | .16 |
| MSD vs dUCB | 0.43 (0.23-0.83) | .091 | .013 |
| Age at HCT (spline 1) | 0.91 (0.83-1) | .053 | |
| Age at HCT (spline 2) | 1.1 (1-1.2) | .061 | |
| BuCy-like vs BuFlu | 0.34 (0.13-0.91) | .029 | |
| BuCy-like vs BuMel-like | 0.77 (0.38-1.4) | .38 | |
| BuCy-like vs Other | 0.59 (0.3-1.2) | .13 | |
| BuCy-like vs TBI-based | 0.91 (0.5-1.8) | .82 | |
| Incidence of aGVHD grades II-IV | |||
| UCB vs MUD | 1 (0.56-1.8) | 1 | .98 |
| MSD vs MUD | 0.59 (0.3-1.2) | .98 | .14 |
| MSD vs UCB | 0.62 (0.3-1.2) | 1 | .15 |
| MSD vs dUCB | 0.56 (0.29-1.1) | .7 | .1 |
| Chemo-based vs TBI-based | 0.56 (0.36-0.83) | .0046 | |
| Age at HCT (spline 1) | 0.97 (0.89-1.1) | .53 | |
| Age at HCT (spline 2) | 1 (0.9-1.1) | .93 | |
| CSA/MMF vs CSA/Mtx | 2 (1.1-3.7) | .017 | |
| CSA/MMF vs CSA/steroids | 1.4 (0.77-2.4) | .31 | |
| No serotherapy vs ATG | 1.3 (0.83-2) | .3 | |
| No serotherapy vs Campath | 0.91 (0.43-1.8) | .73 | |
| Incidence of aGVHD grades III-IV | |||
| UCB vs MUD | 4.2 (1-18) | .357 | .051 |
| MSD vs MUD | 1.4 (0.33-5.9) | 1 | .64 |
| MSD vs UCB | 0.33 (0.091-1.2) | .658 | .094 |
| MSD vs dUCB | 0.43 (0.12-1.6) | 1 | .22 |
| Chemo-based vs TBI-based | 1 (0.45-2) | .9 | |
| Age at HCT (spline 1) | 0.91 (0.79-1.1) | .21 | |
| Age at HCT (spline 2) | 1.1 (0.93-1.3) | .27 | |
| CSA/MMF vs CSA/Mtx | 1.1 (0.31-3.8) | .88 | |
| CSA/MMF vs CSA/steroids | 2 (0.83-5) | .13 | |
| No serotherapy vs ATG | 1.1 (0.53-2.3) | .8 | |
| No serotherapy vs Campath | 0.91 (0.19-4.2) | .88 | |
| Incidence of cGVHD | |||
| UCB vs MUD | 0.3 (0.14-0.67) | .0217 | .0031 |
| MSD vs MUD | 0.5 (0.21-1.1) | .672 | .096 |
| MSD vs UCB | 1.6 (0.62-4.2) | 1 | .3 |
| MSD vs dUCB | 1.5 (0.59-3.8) | 1 | .41 |
| Chemo-based vs TBI-based | 0.43 (0.24-0.83) | .0076 | |
| Age at HCT (spline 1) | 1.1 (0.93-1.2) | .4 | |
| Age at HCT (spline 2) | 0.9 (0.78-1) | .17 | |
| CSA/MMF vs CSA/Mtx | 2.1 (1.1-4.3) | .032 | |
| CSA/MMF vs CSA/steroids | 3.6 (0.83-16) | .093 | |
| No serotherapy vs ATG | 1.1 (0.53-2.5) | .75 | |
| No serotherapy vs Campath | 1 (0.42-2.3) | .94 | |
| cGVHD-LFS | |||
| UCB vs MUD | 0.56 (0.34-1) | .033 | .033 |
| MSD vs MUD | 0.67 (0.4-1) | .073 | .073 |
| MSD vs UCB | 1.1 (0.67-2) | .65 | .65 |
| MSD vs dUCB | 1 (0.56-1.8) | .95 | .95 |
| Chemo-based vs TBI-based | 0.83 (0.59-1.2) | .37 | |
| Age at HCT (spline 1) | 0.95 (0.88-1) | .16 | |
| Age at HCT (spline 2) | 1 (0.95-1.1) | .41 | |
| CSA/MMF vs CSA/Mtx | 1.7 (1.1-2.8) | .025 | |
| CSA/MMF vs CSA/steroids | 1.5 (0.91-2.6) | .14 |
ATG, antithymocyte globulin.